Key facts
- Type: Antidepressant · SSRI
- ATC Code: N06AB03
- Kenya EML 2023: Listed
- Level of Use: Level 4 to 6
This is health education, not medical advice. Never start, stop, or change a medication without speaking to a qualified healthcare professional first.
⚠️
Prescription Only Medicine
Available on prescription from a registered healthcare provider in Kenya.
What it treats
Which conditions is Fluoxetine used for?
Depression · OCD · Bulimia Nervosa · Panic Disorder · PTSD
Overview
What is Fluoxetine?
Fluoxetine was the first selective serotonin reuptake inhibitor (SSRI) to come into widespread use. It has been prescribed for more than three decades and remains one of the most studied antidepressants in the world.
One feature that sets fluoxetine apart from other SSRIs is that it stays in the body significantly longer than most. This means a missed dose has a smaller impact than with other medicines, which is a practical advantage in settings where supply can be irregular.
It is listed in Kenya’s Essential Medicines List 2023 and is widely available across public health facilities in the country.
How it works
What does it do in the brain?
Fluoxetine works by slowing the process by which serotonin, a mood-regulating chemical messenger in the brain, is cleared from the space between nerve cells. By keeping serotonin active for longer, it gradually helps stabilise mood and reduce anxiety. Its effects build and taper more gently than many other antidepressants because it remains in the body for a long time.
Formulations in Kenya
How is it available?
Capsule 20 mg Taken by mouth Widely available
Capsule 40 mg Taken by mouth Available
Oral liquid 20 mg/5 mL Taken by mouth Limited availability
Availability across Africa
Where is it available in Africa and what is it called?
Names and availability vary by country. Always confirm with a local pharmacist or healthcare provider.
| Country | Common Brand Name(s) | Notes |
|---|---|---|
| Kenya | Fluox, Floxet, Deprex, generic | On KEML 2023. Widely available at public and private facilities. |
| Nigeria | Prozac, Flunil, generic | Available in urban private pharmacies and teaching hospitals. |
| South Africa | Prozac, Deprex, generic | Widely available. On South Africa EML. |
| Uganda | Generic fluoxetine | Available at national referral hospitals and urban pharmacies. |
| Tanzania | Generic fluoxetine | Available at referral hospitals and large private pharmacies. |
| Ethiopia | Generic fluoxetine | Available in Addis Ababa and regional referral hospitals. |
| Ghana | Prozac, generic | Available at teaching hospitals and urban pharmacies. |
| Zambia | Generic fluoxetine | Available at University Teaching Hospital and private pharmacies. |
Side effects
What might you feel while taking it?
These are the most commonly reported effects. Not everyone experiences them, and many settle within the first few weeks.
- Nausea and digestive discomfort, especially early on
- Difficulty sleeping. Fluoxetine is usually taken in the morning to reduce this.
- Headaches
- Feeling more anxious or restless in the first two weeks
- Changes in sexual desire or response
- Reduced appetite
- Sweating more than usual
Go to a doctor or emergency room straight away if you notice any of the following.
- Thoughts of harming yourself, especially in young people within the first few weeks of starting
- Agitation, rapid heartbeat, fever, and confusion occurring together at once
- A significant shift into very elevated or erratic mood
Risks
Important risks you should understand before taking this medicine
Read this section carefully.
These are real risks associated with this medicine that every person taking it should be aware of.
- Fluoxetine can increase suicidal thoughts or self-harming behaviours in children, teenagers, and young adults, particularly in the first few weeks of treatment. Close monitoring by family or carers is essential during this period.
- Because fluoxetine stays in the body for weeks, stopping it seems easy but the effects of stopping are delayed and can appear days or weeks later. Never stop without speaking to your doctor.
- Fluoxetine is a potent inhibitor of liver enzymes that process many other medicines. If you are on cancer treatment, blood thinners, or cardiac medicines, this interaction can be clinically significant.
- In people with undiagnosed bipolar disorder, fluoxetine can trigger a manic episode. If someone on fluoxetine suddenly becomes unusually energetic, sleeps very little, or behaves erratically, they should see a doctor promptly.
- Fluoxetine and anti-inflammatory painkillers like ibuprofen used together significantly increase the risk of stomach bleeding.
Who should not take it
Important warnings before starting
Tell your doctor about all your medical conditions, allergies, and other medicines before starting Fluoxetine.
- You are currently taking medicines from the MAOI class
- You have had a serious allergic reaction to fluoxetine in the past
Special care needed
Situations that need extra attention
- Tell your doctor if you have liver problems
- Tell your doctor if you have ever had episodes of very high mood or manic behaviour
- If you are on cancer treatment, blood thinners, or heart medicines, your doctor must review these alongside fluoxetine before you start
- Elderly patients should discuss the appropriate starting approach with their doctor
Pregnancy
There is some evidence of a small risk with fluoxetine in early pregnancy. If you are pregnant or planning a pregnancy, talk to your doctor before making any changes.
Breastfeeding
Fluoxetine passes into breast milk more than some other antidepressants. If you are breastfeeding, your doctor may consider whether another SSRI would be more suitable.
Other medicines
Medicines and substances that can interact with it
Always tell your doctor and pharmacist about every medicine, supplement, and herbal remedy you take, including those bought without a prescription.
- MAOIs: A potentially life-threatening combination. There must be a significant gap between stopping one and starting the other. Never combine without specific medical guidance.
- Tamoxifen (used in breast cancer treatment): Fluoxetine can reduce how well tamoxifen works. If you are on cancer treatment, your oncologist and prescriber must communicate.
- Blood thinners such as warfarin: The blood-thinning effect may increase, raising bleeding risk.
- Alcohol: Can worsen dizziness, drowsiness, and other side effects.
Tests and follow-up
What your doctor will monitor
- A follow-up in the first few weeks to check how you are tolerating the medicine
- Report any new or worsening thoughts of self-harm, particularly if you are a young person
- If you are elderly, your doctor may periodically check your blood sodium levels
- Long-term users will have periodic reviews
Stopping this medicine
What happens if you stop taking it?
Because fluoxetine stays in the body for a long time, withdrawal effects when stopping are generally less pronounced than with other antidepressants. However, you should still reduce gradually and only with your doctor's guidance.
In Kenya
What you should know about this medicine in Kenya
Fluoxetine is one of the most affordable and accessible antidepressants in Kenya, available as a generic medicine at many public facilities.
Its long duration in the body makes it particularly practical in settings where supply chains can be unpredictable.
People in Kenya sometimes worry that antidepressants will change who they are or cause dependence. Fluoxetine is not addictive in the way that some other medicines are. Addressing these concerns openly with a healthcare provider makes a significant difference to treatment outcomes.
Sources
References
- Ministry of Health, Kenya. (2023). Kenya Essential Medicines List 2023. Nairobi: Ministry of Health.
- Ministry of Health, Kenya. (2023). Kenya National Medicines Formulary, 1st Edition. Nairobi: Ministry of Health.
- Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs. The Lancet, 391(10128), 1357-1366.
- World Health Organization. (2023). Model List of Essential Medicines, 23rd Edition. Geneva: WHO.